Back to today’s briefing

Story perspectives

Vera Therapeutics' Drug Cuts Kidney Disease Protein by 46%

6/3/2025

48 9

Summary

Story summary

Vera Therapeutics announced a promising breakthrough: their drug atacicept slashed toxic protein levels in IgA nephropathy patients by 46% over nine months, a stark contrast to the 7% reduction seen in the placebo group. This Phase 3 study, involving 431 participants, paves the way for a potential FDA submission by year-end, offering hope against a condition that can lead to kidney failure.

1 of 1

Story summary

Vera Therapeutics announced a promising breakthrough: their drug atacicept slashed toxic protein levels in IgA nephropathy patients by 46% over nine months, a stark contrast to the 7% reduction seen in the placebo group. This Phase 3 study, involving 431 participants, paves the way for a potential FDA submission by year-end, offering hope against a condition that can lead to kidney failure.